The company has significantly advanced this course of an new treatment for cardiac amyloidosis, utilizing Attruby. Initial patient data suggests promising outcomes for patients diagnosed by the severe condition. This https://attruby762823.blogoscience.com/48875242/bridgebio-progresses-attr-cm-therapy-using-the-drug